Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 15/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216689 | 0.74 | KMT2A (0.72) | AKR1B1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL23915519 | 0.73 | POLB (0.67) | POLBAKR1B1MAPTKMT2A | |
| SCHEMBL15597471 | 0.72 | MAPT (0.68) | POLBMAPTKMT2AMEN1 | |
| SCHEMBL6294641 | 0.71 | AKR1B1 (0.75) | POLBAKR1B1 | |
| SCHEMBL18900937 | 0.70 | CMA1 (0.73) | POLBAKR1B1CMA1 | |
| SCHEMBL6890822 | 0.70 | MAPT (1.00) | POLBAKR1B1MAPTKMT2A | |
| SCHEMBL9327258 | 0.69 | MAPT (0.78) | POLBAKR1B1MAPTKMT2ACMA1 | |
| SCHEMBL23914949 | 0.69 | MAPT (0.67) | POLBAKR1B1MAPTKMT2A | |
| SCHEMBL9215584 | 0.69 | AKR1B1 (0.77) | AKR1B1MAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL9218514 | 0.68 | AKR1B1 (0.80) | AKR1B1MAPTKMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995003053-A1 | OXOPHTHALAZINES FOR TREATING CACHEXIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-02 | — | — | WO | disclosed |